Clinical trials: Severe Infection
Clostridium Difficile Colitis
Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
Once the lab test is positive for c. diff, the investigators will order the patient to have PEG 3350 solution, one 8oz glass every ten minutes until 6 liters are gone, but if still not clear 2 more liters may be ordered.
- Trial name
- COLITIS (NCT01630096)
- Testing
- Nu-Lytely
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ascension Health
COVID-19
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
- Trial name
- NCT04679350
- Testing
- hzVSF-v13
- Where
- 3 sites in South Korea
- Volunteers
- 1 people
- Sponsor
- ImmuneMed, Inc.
Sepsis, Severe Sepsis
Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03752489
- Testing
- Treatment-specific InSight, InSight
- Volunteers
- 51,645 people, healthy volunteers welcome
- Sponsor
- Dascena
Onychomycosis
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of…
- Trial name
- NCT01841996
- Testing
- ME1111 solution, Vehicle Solution
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Dengue Shock Syndrome
Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)
Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are among the leading causes of pediatric hospitalization in Asia.Mortality rates range from 1% at centres experienced in fluid resuscitation, to upto 44% in…
- Trial name
- NCT00966628
- Testing
- Hypertonic sodium lactate, Ringer's lactate
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Innogene Kalbiotech Pte. Ltd
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Severe Sepsis
Effect of a Sepsis Prediction Algorithm on Clinical Outcomes
In this clinical outcomes analysis, the effect of a machine learning algorithm for severe sepsis prediction on in-hospital mortality, hospital length of stay, and 30-day readmission was evaluated.
- Trial name
- NCT03960203
- Testing
- InSight
- Volunteers
- 75,147 people, healthy volunteers welcome
- Sponsor
- Dascena
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
Severe Sepsis
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
- Trial name
- NCT00334828
- Testing
- eritoran tetrasodium
- Where
- 251 sites in United States, Argentina and 22 more
- Volunteers
- 2,000 people
- Sponsor
- Eisai Inc.
Chagas Disease
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.
- Trial name
- NCT06632600
- Testing
- LXE408, Benznidazole
- Where
- 22 sites in United States, Argentina and 2 more
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Conjunctivitis
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive…
- Trial name
- NCT02432807
- Testing
- Vancomycin 1.1%
- Where
- 16 sites in United States
- Volunteers
- 303 people
- Sponsor
- Kurobe LLC
COVID-19 Infection, COVID-19 Vaccine Adverse Reaction
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Booster Vaccine (LEM-mR203) in healthy adults aged at 19 to 55 years
- Trial name
- NCT06032000
- Testing
- LEM-mR203
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lemonex
Severe Respiratory Disease
Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk
Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash aspirates in children at high risk for severe LRI disease (hospitalized at <2 years of age).
- Trial name
- NCT00192439
- Testing
- High Risk Respiratory Disease
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 1,500 people
- Sponsor
- MedImmune LLC
COVID-19 Respiratory Infection, COVID-19
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients
The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR.
- Trial name
- NCT06452069
- Testing
- IMMUNO19
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Biodex S.A
Hidradenitis Suppurativa (HS)
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions.
- Trial name
- NCT04430855
- Testing
- Upadacitinib
- Where
- 26 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- AbbVie
Severe Acute Respiratory Syndrome Coronavirus 2
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.
- Trial name
- DMMETCOV19-2 (NCT04625985)
- Testing
- Metformin Glycinate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.